Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Conference News TCT 2018

Novel LAA Closure Device Shows Promise in Early Experience

L.A. McKeown

September 22, 2018

News Industry News

Thrombolytic Science Initiates Phase 2 Clinical Trial of its Novel Treatment Regimen for Ischemic Stroke

September 05, 2018

News Conference News ESC 2018

ASCOT Legacy: Calcium Channel Blockers, Statins Confer Long-term Survival Benefits in Hypertensive Patients

L.A. McKeown

August 31, 2018

News Daily News

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Caitlin E. Cox

August 15, 2018

News Daily News

Speed Still Critical for Endovascular Therapy Patients Treated Soon After Stroke: MR CLEAN

Caitlin E. Cox

March 30, 2018

News Conference News ISET 2018

WISE LE Data Build the Case for Embolic Protection in Lower-Extremity Atherectomy

Caitlin E. Cox

February 13, 2018

News Daily News

Tool Predicts Stroke Risk in Patients With Systolic Dysfunction After MI

Todd Neale

February 12, 2018

News Industry News

New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment

January 29, 2018

News Daily News

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

L.A. McKeown

January 02, 2018

Advertisement

Novel LAA Closure Device Shows Promise in Early Experience

Thrombolytic Science Initiates Phase 2 Clinical Trial of its Novel Treatment Regimen for Ischemic Stroke

ASCOT Legacy: Calcium Channel Blockers, Statins Confer Long-term Survival Benefits in Hypertensive Patients

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Speed Still Critical for Endovascular Therapy Patients Treated Soon After Stroke: MR CLEAN

WISE LE Data Build the Case for Embolic Protection in Lower-Extremity Atherectomy

Tool Predicts Stroke Risk in Patients With Systolic Dysfunction After MI

New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content